GAZYVA, in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, is indicated for the treatment of adult patients with previously...
INDICATIONS AND USAGE 1.1 Chronic Lymphocytic Leukemia (CLL) GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic …
GAZYVA® (obinutuzumab) Treatment, Indications, Dosing & Safety
Learn about GAZYVA® (obinutuzumab) for first-line, R/R follicular lymphoma & first-line CLL. See important safety including Boxed Warnings for more information.
Gazyva: Package Insert / Prescribing Information / MOA
Nov 20, 2025 · Gazyva package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
- [PDF]
GAZYVA Dosing
For your convenience, this guide has been organized in 2 sections to highlight the differences in GAZYVA use in FL and CLL. Please be sure to refer to the appropriate section for the patient you …
Jan 4, 2024 · Used as a single agent for maintenance therapy as second-line consolidation therapy or extended dosing in rituximab-refractory patients treated with obinutuzumab and bendamustine for …
Gazyva (Genentech, Inc.): FDA Package Insert - MedLibrary.org
Dec 19, 2025 · GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia.
GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia.
GAZYVA (obinutuzumab) is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
- [PDF]
CDS Body - Roche
GAZYVA in combination with bendamustine, followed by GAZYVA maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond to, or who progressed during …